Thymopentin Enhances Antitumor Immunity Through Thymic Rejuvenation and T Cell Functional Reprogramming

Area of Science:

• Immunology
• Oncology
• Pharmacology

Background:

• T cell dysfunction is a key challenge in cancer immunotherapy, leading to treatment resistance.
• Existing therapies like immune checkpoint blockade and adoptive cell transfer have limitations.
• Thymopentin (TP5), an immunomodulatory peptide, has unexplored anticancer potential.

Purpose of the Study:

• To investigate the antitumor efficacy of TP5.
• To elucidate the immunological mechanisms underlying TP5's effects.
• To assess TP5's potential as an adjuvant for T cell-based cancer therapies.

Main Methods:

• TP5 efficacy was tested in murine models of melanoma, colorectal, and hepatocellular carcinoma.
• Immune cell populations and functions were analyzed using flow cytometry, ELISAs, and immunofluorescence.
• Synergistic effects of TP5 with adoptive T cell therapies were evaluated.

Main Results:

• TP5 significantly suppressed tumor growth via T cell-dependent mechanisms across various cancer models.
• TP5 promoted thymic rejuvenation and restored peripheral T cell immunity, even in immunocompromised settings.
• TP5 preserved T cell effector function, reduced exhaustion, and enhanced adoptive T cell therapy outcomes.

Conclusions:

• TP5 is a potent immunomodulator with significant anticancer activity.
• TP5 addresses limitations in current T cell therapies by enhancing T cell function and combating thymic involution.
• TP5 demonstrates strong potential for clinical translation in cancer treatment, particularly in combination therapies.